Skip to main content Back to Top
Advertisement

7/28/2021

Lorazepam Tablets

Products Affected - Description

    • Lorazepam tablet, Major, 0.5 mg, bottle, 100 count, NDC 00904-6007-60
    • Lorazepam tablet, Major, 0.5 mg, unit-dose blister pack, 100 count, NDC 00904-6007-61
    • Lorazepam tablet, Major, 1 mg, unit-dose blister pack, 100 count, NDC 00904-6008-61
    • Lorazepam tablet, Teva, 0.5 mg, bottle, 100 count, NDC 00591-0240-01
    • Lorazepam tablet, Teva, 0.5 mg, bottle, 500 count, NDC 00591-0240-05
    • Lorazepam tablet, Teva, 0.5 mg, bottle, 1000 count, NDC 00591-0240-10
    • Lorazepam tablet, Teva, 1 mg, bottle, 100 count, NDC 00591-0241-01
    • Lorazepam tablet, Teva, 1 mg, bottle, 500 count, NDC 00591-0241-05
    • Lorazepam tablet, Teva, 1 mg, bottle, 1000 count, NDC 00591-0241-10

Reason for the Shortage

    • Aurobindo refuses to provide availability information.
    • Bausch Health has Ativan tablets available.
    • Leading has lorazepam tablet presentations available and is shipping supplies regularly.
    • Major did not provide a reason for the shortage.
    • Mylan has discontinued all bottled presentations.
    • Mylan Institutional discontinued all unit-dose blister pack presentations.
    • Sandoz discontinued all lorazepam presentations.
    • Teva did not provide a reason for the shortage. Teva has new NDC numbers for the 2 mg tablets.

Available Products

    • Ativan tablet, Bausch Health, 0.5 mg, bottle, 100 count, NDC 00187-0063-01
    • Ativan tablet, Bausch Health, 1 mg, bottle, 100 count, NDC 00187-0064-01
    • Ativan tablet, Bausch Health, 1 mg, bottle, 1000 count, NDC 00187-0064-10
    • Ativan tablet, Bausch Health, 2 mg, bottle, 100 count, NDC 00187-0065-01
    • Lorazepam tablet, Leading, 0.5 mg, bottle, 100 count, NDC 69315-0904-01
    • Lorazepam tablet, Leading, 0.5 mg, bottle, 500 count, NDC 69315-0904-05
    • Lorazepam tablet, Leading, 0.5 mg, bottle, 1000 count, NDC 69315-0904-10
    • Lorazepam tablet, Leading, 1 mg, bottle, 100 count, NDC 69315-0905-01
    • Lorazepam tablet, Leading, 1 mg, bottle, 500 count, NDC 69315-0905-05
    • Lorazepam tablet, Leading, 1 mg, bottle, 1000 count, NDC 69315-0905-10
    • Lorazepam tablet, Leading, 2 mg, bottle, 100 count, NDC 69315-0906-01
    • Lorazepam tablet, Leading, 2 mg, bottle, 500 count, NDC 69315-0906-05
    • Lorazepam tablet, Leading, 2 mg, bottle, 1000 count, NDC 69315-0906-10
    • Lorazepam tablet, Major, 1 mg, bottle, 100 count, NDC 00904-6008-60
    • Lorazepam tablet, Major, 2 mg, bottle, 100 count, NDC 00904-6009-60
    • Lorazepam tablet, Major, 2 mg, unit-dose blister pack, 100 count, NDC 00904-6009-61
    • Lorazepam tablet, Teva, 2 mg, bottle, 100 count, NDC 00093-3427-01
    • Lorazepam tablet, Teva, 2 mg, bottle, 500 count, NDC 00093-3427-05
    • Lorazepam tablet, Teva, 2 mg, bottle, 1000 count, NDC 00093-3427-10

Estimated Resupply Dates

    • Teva has lorazepam 0.5 mg tablet presentations on back order and the company estimates release dates of late-July 2021. The 1 mg tablets in 500 and 1000 counts are on back order and the company estimates release dates of early-August 2021. The 1 mg tablets in 100 count are on back order and the company estimates a release date in late-July 2021.
    • Major has lorazepam 0.5 mg tablets in 100 count bottles on back order and the company cannot estimate a release date. The 0.5 mg tablets in 100 count unit-dose packs are on back order and the company estimates a release date of late-July 2021. The 1 mg tablets in 100 count unit-dose packs are on back order and the company estimates a release date in mid-August 2021.

Updated

Updated July 28, 2021 by Leslie Jensen, PharmD, Drug Information Specialist. Created October 4, 2018 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2021, Drug Information Service, University of Utah, Salt Lake City, UT.

ADVERTISEMENT

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.